Loading data for KRRO — first visit, this takes a few seconds.

Preisalarm

Korro Bio Inc. (KRRO)

NasdaqCM: KRRO · Echtzeitkurs · USD

13.22

+0.08 (0.61%)

Zum Schluss: Aug 18, 2026, 8:00 PM

0.61% (1D)

Keine Daten verfügbar

Geld	n/a
Marktkapitalisierung	194.67 Mio
Umsatz (TTM)	2.38 Mio
Nettogewinn (TTM)	-106.64 Mio
Beta	2.21
EPS (ttm)	-9.96
KGV (TTM)	n/a
Forward-KGV	-2.96
KBV (TTM)	1.88
KUV (TTM)	81.73
Earnings Date	Nov 12, 2026

Brief	n/a
Volumen	70,527
Ø Vol. (20D)	193,619
Eröffnung	13.03
Vortagesschluss	13.14
Tagesspanne	12.63 - 13.26
52-Wk Range	5.20 - 55.89
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über KRRO

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The ...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Oct 3, 2019

Mitarbeiter 57

Börse NasdaqCM

Tickersymbol KRRO

Website https://www.korrobio.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Korro Bio 6.39 Mio, ein Anstieg von 181.46% im Vergleich zum Vorjahr (2.27 Mio). Der Gewinn lag bei -117.26 Mio, ein Anstieg von 40.3 %.

Finanzberichte

Gewinnüberraschung

Korro Bio hat die Quartalszahlen am Aug 6, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit -100.00% Rückgang im Jahresvergleich.

EPS von -1.07 übertrifft die Erwartungen um 0.21, mit 60.95% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Korro Bio Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 12, 2026, vor Börseneröffnung.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 1 Woche · Zacks

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

vor 1 Monat · Zacks

Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?

Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

vor 2 Monaten · Zacks

Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?

Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near t...

vor 2 Monaten · Simply Wall St.

One Korro Bio Insider Raised Stake By 19% In Previous Year

Viewing insider transactions for Korro Bio, Inc.'s ( NASDAQ:KRRO ) over the last year, we see that insiders were net...

vor 3 Monaten · Zacks

What Makes Korro Bio, Inc. (KRRO) a New Buy Stock

Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seite 1 von 2

Korro Bio Inc. (KRRO)